McGuire Investment Group LLC Purchases 472 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

McGuire Investment Group LLC raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 44,665 shares of the company’s stock after buying an additional 472 shares during the quarter. Medpace comprises about 2.1% of McGuire Investment Group LLC’s investment portfolio, making the stock its 17th largest holding. McGuire Investment Group LLC owned approximately 0.14% of Medpace worth $14,839,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Iron Triangle Partners LP acquired a new position in Medpace during the 3rd quarter valued at about $64,371,000. Clearbridge Investments LLC increased its holdings in shares of Medpace by 55.1% during the second quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock valued at $166,343,000 after acquiring an additional 143,481 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Medpace by 62.3% in the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after purchasing an additional 119,257 shares during the last quarter. Wellington Management Group LLP boosted its stake in Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after purchasing an additional 109,886 shares in the last quarter. Finally, DF Dent & Co. Inc. grew its position in Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock worth $53,841,000 after purchasing an additional 105,659 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

MEDP opened at $344.07 on Friday. The firm has a fifty day moving average price of $339.66 and a 200 day moving average price of $356.00. Medpace Holdings, Inc. has a 1 year low of $286.76 and a 1 year high of $459.77. The stock has a market cap of $10.69 billion, a P/E ratio of 30.13, a P/E/G ratio of 1.77 and a beta of 1.36.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MEDP. Truist Financial lowered their price objective on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Baird R W cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Redburn Atlantic assumed coverage on Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective on the stock. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Robert W. Baird increased their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a report on Monday, November 25th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $380.56.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.